Bladder tumors rank second in frequency among genitourinary tumors. The disease occurs more often among men, with a gender ratio of 3:1. About two-thirds of those affected are registered over the age of 65. There is a difference in the incidence of the disease according to race and geographic location. A higher incidence is observed among Caucasians and highly industrialized countries. The incidence is the lowest among Asian countries. In 2012, 7,549 patients with bladder cancer were registered in Bulgaria, 1,144 new cases were registered, and 425 people died from the disease during the year. Follow-up shows a permanent trend towards an increase in bladder cancer cases, while the mortality rate does not show any significant changes .

Papilloma viruses

Papillomaviruses are again suspected as the causative agents of this type of cancer, which, considering the very common inflammatory diseases of the urinary bladder (cystitis), fits our inflammatory-microbial theory of the origin of cancer.

A leading part of the international standards for the treatment of urothelial tumors is intravesical instillation with BCG in stages in situ and 1/2a.

Different strains of BCG and different preparations are used, usually containing a higher dose than the standard BCG ampoules for immunization against tuberculosis. The Bulgarian preparation KALGEVAX, for example, contains 11.25 mg, but 2-3 ampoules are administered weekly for 6 weeks and then monthly for 6-12 months after surgery.

In patients who have undergone intravesical BCG therapy, we wait at least 6 months before starting CATRAPS therapy to avoid any possibility of BCG accumulation in the body or of causing side effects from BCG instillations, which are well described above in the text. 

Papillomaviruses are again suspected as the causative agents of this type of cancer, which, considering the very common inflammatory diseases of the urinary bladder (cystitis), fits our inflammatory-microbial theory of the origin of cancer.

Analysis of data from treatment with Catraps

In our treatment, patients are not selected and it often happens that they are in stage 3-4, when they have undergone all types of "standard" therapy and after having undergone more than 3 - 5 or 8 TURs (trans-urethral resection of tumors in the bladder).

     If we show over 3-year survival in the absence of recurrence, (recurrences are most common in the first year after Tu-TUR operation), the percentages become 57.5%. Our impressions of all our patients with this diagnosis is their almost 100% improvement, expressed in the absence of recurrence, proven by regular ultrasounds and much less often by cystoscopy.

Our patients live a wonderful quality of life, without the severe side effects of intravesical instillation. Ruthless global statistics show that smoking is a major risk factor for the formation of tumors in the bladder.

Всеки знае за вредата от тютюнопушенето върху устната кухина, ларингса и белите дробове , но е по-малко известен факт е въздействието на тютюнопушенето върху органите на пикочната система, чрез които става излъчването му от организма т.е. пикочният мехур и червата.  

With the application of KATRAPS, the mechanism of action is similar, but it is even more strongly affected by the intradermal application of BCG, and thus the central organs of the immune system are engaged and together with the peripheral ones (in the bladder) provide a powerful cellular immune response with the destruction of cancer cells cells from your own body. And this happens without observing the unpleasant side effects of intravesical instillation.